Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...
In the past, investors bought into a recovery story that is now completed. Today, in a low-growth market, we believe that the group’s operating excellence (16% EPS CAGR over 2017/20e and PEG of 0.8x) justifies that investors still show an interest in a stock which is down 17% since January! We initiate coverage with a Buy rating (FV EUR104).
We raise our DCF-derived Fair Value to EUR48 from EUR40 following the analysts’ meeting held yesterday, as we reduce our company beta to 1.47 from 1.66 in our multidimensional approach in order to better reflect EasyVista’s improving earnings momentum. In 2018, the company is poised to benefit from solid revenue growth driven by renewable licensing, strong operating leverage, a strengthened US organisation, and cash flow turnaround.
According to Reuters, Italian state lender CDP intends to buy shares in Telecom Italia, up to 5%, on the market or in block orders. CDP, does not currently hold any shares in TIM, a source close to the matter confirmed. The decision on the share acquisition, will be taken at CDP’s board meeting on Thursday. • Vivendi currently owns 24.9% of TIM, while Elliott owns 5.75% of the operator and the battle is raging over the group’s strategy and board. We view CDP’s entry into TIM’s capital as a back up for Elliott’s plan. Indeed, the Italian government and regulators have sounded very much in favou...
Novartis: (BUY-Top Picks, Fair Value CHF93 (+20%)) Poised for strong growth profile over the next five years As an introductory comment to the MTM meeting held yesterday in Basel, new CEO Vas Narasimhan delivered a message in the form of a strategic roadmap for the period which opens for the company: Novartis will focus on innovative medicines and will pay particular attention to trust and reputation after several issues. We view Novartis as well-positioned to offer one of the most visible and attractive growth profiles in the European healthcare sector over the next five years. BUY
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.